Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (151)	1/15/2001 8:31:07 AM
From: Alfred W. Post	Read Replies (1) \| Respond to of 362

Just had a long discussion with Investor Relations at Novartis. They attribute the sharp drop in share prices of TTP oly to stockmarketconditions, alluding to the burst of the NASDAQ bubbel when the stock was at $65 and that TTP went down in sympathy with the NASDAQ. There is no negative news as far as they can see it. The Schizophrenia procuct (sorry I do not remember the name) is in stage III and they are confident that they will get FDA approval. They are not shareholders of TTP but will share in future profits when the product will be on the market which they assume will happen end of 02. They consider the Schizophrenis market major. I could not get any information from them concerning the cooperation of TTP with Schering. TTP is one of 16 firms Novartis has research commitments. The tone of the discussion was upbeat. Fred